Updates in the treatment of CLL from EHA 2024: BTK and BCL2 inhibitor combinations, BTK degraders, and more
VJHemOnc Podcast
Intro
Experts explore the latest updates in the treatment of chronic lymphocytic leukemia (CLL) and Richters transformation, including combinations of BTK and BCL2 inhibitors in first-line and relapse refractory settings from trials such as Sequoia and Nubrutinib with Sirotoclax. Promising combinations like xanabarutinib with Serontoclax are discussed, along with future randomized clinical trials comparing various therapies.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
